Denali Therapeutics Inc.
DNLI
$19.80
$0.341.75%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -128.45M | -128.55M | -126.90M | -124.12M | -132.97M |
| Total Depreciation and Amortization | 3.76M | 3.78M | 3.86M | 3.96M | 3.21M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 20.98M | 21.21M | 21.97M | 21.58M | 20.22M |
| Change in Net Operating Assets | -27.50M | 5.02M | -6.22M | 23.29M | -21.93M |
| Cash from Operations | -131.20M | -98.54M | -107.30M | -75.30M | -131.47M |
| Capital Expenditure | -2.47M | -1.52M | 1.38M | -4.28M | -5.08M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 96.93M | 22.29M | 56.45M | 162.21M | 23.83M |
| Cash from Investing | 94.46M | 20.77M | 57.83M | 157.94M | 18.75M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -17.00K | -16.00K | -1.36M | -2.43M | -4.36M |
| Issuance of Common Stock | 19.06M | 920.47M | 583.00K | 4.06M | 595.00K |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 200.00M | -728.32M | -- | -- | -- |
| Cash from Financing | 219.04M | 192.13M | -778.00K | 1.62M | -3.76M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 182.30M | 114.36M | -50.24M | 84.26M | -116.48M |